Other, Publications Nonclinical efficacy, pharmacokinetic profile and pharmacokinetic/pharmacodynamic (PK/PD) correlation of ALG-125755, a GalNAc conjugated siRNA, for functional cure of chronic hepatitis B
Other Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development
Other, Publications Mutations L50F, E166A and L167F in SARS-CoV-2 3CLpro are Selected by a Protease Inhibitor In Vitro and are Associated with Resistance
Other, Publications Discovery of ALG-097558, a Novel 3CL Protease Inhibitor with Activity in the SARS-CoV-2 Hamster Infection Model
Other, Publications Discovery and Antiviral Activity of the Novel 3CL Protease Inhibitor ALG-097558 in the SARS-CoV-2 Hamster Infection Model
Other, Publications Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model
Other, Publications The HBV siRNA, ALG-125755, demonstrates a favorable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model
Other, Publications Hepatitis B Surface Antigen (HBsAg) is Significantly Reduced by the HBV small interfering RNA (siRNA) ALG-125755 in HBV Infected Cells and the AAV HBV Mouse Model
Other, Publications Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model